Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
Viviane Cordeiro Veiga, João Antônio Gonçalves Garreta Prats, Danielle Leão Cordeiro de Farias, et al.
BMJ (2021), pp. n84-n84
Open Access | Times Cited: 382

Showing 1-25 of 382 citing articles:

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Anthony Gordon, Paul Mouncey, Farah Al-Beidh, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 16, pp. 1491-1502
Open Access | Times Cited: 1733
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 397, Iss. 10285, pp. 1637-1645
Open Access | Times Cited: 1016
Drug treatments for covid-19: living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Dena Zeraatkar, et al.
BMJ (2020), pp. m2980-m2980
Open Access | Times Cited: 796
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
Peré Domingo, Isabel Mur, Gràcia Mateo, et al.
JAMA (2021) Vol. 326, Iss. 6, pp. 499-499
Open Access | Times Cited: 600
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, et al.
The Lancet (2021) Vol. 397, Iss. 10274, pp. 605-612
Open Access | Times Cited: 531
The signal pathways and treatment of cytokine storm in COVID-19
Lan Yang, Xueru Xie, Zikun Tu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 498
COVID-19: breaking down a global health crisis
Saad I. Mallah, Omar Ghorab, Sabrina Al-Salmi, et al.
Annals of Clinical Microbiology and Antimicrobials (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 305
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Peter Horby, Guilherme Pessoa-Amorim, Leon Peto, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 302
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic
Kelvin Kai‐Wang To, Siddharth Sridhar, Kelvin Hei‐Yeung Chiu, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 507-535
Open Access | Times Cited: 297
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers, Megan Crichton, Pieter Goeminne, et al.
European Respiratory Journal (2021) Vol. 57, Iss. 4, pp. 2100048-2100048
Open Access | Times Cited: 201
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
Oliver J. McElvaney, Gerard F. Curley, Stefan Rose‐John, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 6, pp. 643-654
Open Access | Times Cited: 181
COVID‐19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts
Alison E. John, Chitra Joseph, Gisli Jenkins, et al.
Immunological Reviews (2021) Vol. 302, Iss. 1, pp. 228-240
Open Access | Times Cited: 165
Interleukin-6 blocking agents for treating COVID-19: a living systematic review
Lina Ghosn, Anna Chaimani, Theodoros Evrenoglou, et al.
Cochrane library (2021) Vol. 2021, Iss. 3
Open Access | Times Cited: 157
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 139
Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup
Eric J. Rubin, Dan L. Longo, Lindsey R. Baden
New England Journal of Medicine (2021) Vol. 384, Iss. 16, pp. 1564-1565
Open Access | Times Cited: 138
Is IL-6 a key cytokine target for therapy in COVID-19?
Simon A. Jones, Christopher A. Hunter
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 337-339
Open Access | Times Cited: 137
Pulmonary fibrosis secondary to COVID-19: a narrative review
Suzana Érico Tanni, Alexandre Todorovic Fabro, André Luís Pereira de Albuquerque, et al.
Expert Review of Respiratory Medicine (2021) Vol. 15, Iss. 6, pp. 791-803
Closed Access | Times Cited: 131
BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees
Ahmed N. Alghamdi, Mohammed I. Alotaibi, Adel S. A. Alqahtani, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 120
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19
Nils Kappelmann, Robert Dantzer, Golam M. Khandaker
Psychoneuroendocrinology (2021) Vol. 131, pp. 105295-105295
Open Access | Times Cited: 117
Clinical features and prognostic factors in Covid-19: A prospective cohort study
Sanne de Bruin, Lieuwe D. J. Bos, Marian A. van Roon, et al.
EBioMedicine (2021) Vol. 67, pp. 103378-103378
Open Access | Times Cited: 115
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
Federico Angriman, Bruno L. Ferreyro, Lisa Burry, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 6, pp. 655-664
Open Access | Times Cited: 105
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 105
The role of IL-6 and IL-6 blockade in COVID-19
Nicola Potere, Alberto Batticciotto, Alessandra Vecchiè, et al.
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 6, pp. 601-618
Closed Access | Times Cited: 101
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Qin Ning, Di Wu, Xiaojing Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 69
Page 1 - Next Page

Scroll to top